CYP19A1 and metabolic syndrome: These findings indicate that even in patients who are overweight/obese or with elevated surrogate serum markers of the metabolic syndrome, letrozole at the standard dose 2.5 mg/day achieves systemic estradiol and estrone suppression, reflecting adequate aromatase inhibition at extremes of BMI.